⨯

working

Sign in

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account


Sign In
Not a commercial user? Register here for our wider research bundle

More Content

More Content

ImmuPharma presents plans for pharmacokinetic (PK) for Lupuzor treatment by the end of the current quarter

Companies: ImmuPharma plc

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' Lupuzor licensing deal

Companies: ImmuPharma plc

ImmuPharma raise £3.55m 'giving validation' from long-term shareholder Lanstead

Companies: ImmuPharma plc

ImmuPharma set to meet FDA in December to discuss phase III lupus clinical trial

Companies: ImmuPharma plc

ImmuPharma raise £3.55m 'giving validation' from Lanstead and Lupuzor partner Avion

Companies: ImmuPharma plc

Copyright © 2022 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top